JPRN-jRCT2031230059招募中1 期
An Open-label, Multinational, Multicenter, Single-arm Phase 1b/2 Study to Evaluate Efficacy and Safety of Oral HH2853, a Selective EZH1/2 Inhibitor, in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma - HH2853 Phase 1b/2 study with Relapsed/Refractory PTC
Onishi Shintaro0 个研究点目标入组 100 人开始时间: 2023年4月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Be able to understand and voluntarily sign the informed consent form (ICF).
- •2.Male or female patients aged 18 years or older.
- •3.Tumor types:
- •Dose Escalation: relapses or refractory NHL
- •Phase 1b dose expansion part and Phase 2:
- •relapses or refractory PTCL
- •4.All patients must have measurable lesions
- •5.Patients with prior radiotherapy can be enrolled
- •6.Availability of qualified tissue samples by patient for pathological diagnosis by the central laboratory.
- •7.The Eastern cooperative oncology group (ECOG) score 0-1
- •8. Life expectancy at least 3 months before starting HH2853 treatment.
- •9.Sufficient bone marrow, liver and renal functions without treatment with cell growth factor in 7 days, and platelet, red blood cell or blood transfusions in 14 days before the hematological evaluation during screening:
- •10.Requirement for sufficient time interval between the last antitumor treatment and the first administration of HH2853:
排除标准
- •1.Previous treatment with EZH2 or EZH1/2 inhibitors.
- •2.Central nervous system invasion
- •3.Any previous history of bone marrow malignancy, including myelodysplastic syndrome (MDS).
- •4.Previous or current combination of other primary malignancies, or other malignant tumors.
- •5.Received medications that are known potent CYP3A4 inducers, inhibitors within 1 week prior to first dose.
- •6.Received inactivated vaccines and live attenuated vaccines within 2 weeks prior to first dose.
- •7.Any prior treatment related clinically significant toxicities have not resolved to Grade 0 or 1 per CTCAE version 5.01, or prior treatment related toxicities are clinically unstable and clinically significant at the time of enrollment.
- •8.Major surgery or significant traumatic injury within 4 weeks prior to the first dose of the study drug.
- •9.Inability to take oral medication, malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability of HH2853.
- •10.Clinically significant cardiovascular disease meeting
- •11.Known HIV infection with a history of acquired immunodeficiency syndrome (AIDS) defining opportunity infection within the past 12 months, active hepatitis B and hepatitis C.
- •12.Venous thrombosis or pulmonary embolism occurred within least 3 months before starting HH2853.
- •13.Any diseases or medical conditions that may be unstable or influence their safety or study compliance, including solid organ transplantation, abuse of psychotropic medication, alcohol abuse or history of drug abuse.
- •14.Other serious illnesses or medical conditions that, at the Investigators discretion, may influence study results, including serious infection, diabetes, cardiovascular and cerebrovascular diseases or lung disease.
- •15.Known to be allergic to any component of HH2853.
- •16.Any active interstitial lung disease (ILD), drug induced ILD, radiation pneumonia requiring or receiving steroid treatment.
- •17.There is a third space effusion that cannot be controlled by drainage or other methods.
- •18.Pregnant or breast feeding patients.
- •19.Males and females of childbearing potential.
研究者
相似试验
进行中（未招募）
1 期
A clinical study in subjects with multiple sclerosis who successfullycompleted the MS-LAQ-301 (ALLEGRO) study, to assess the safety oflaquinimod (experimental drug) when taken for a long period of time andhow it affects the course of the disease.aquinimod is developed for the treatment of relapsing remitting multiple sclerosis.MedDRA version: 19.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-012989-30-EETeva Pharmaceutical Industries Ltd542
进行中（未招募）
1 期
A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-302 (BRAVO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis - NDaquinimod is developed for the treatment of relapsing remitting multiple sclerosis.MedDRA version: 9.1Level: PTClassification code 10063399EUCTR2009-015815-42-ITTeva Pharmaceutical Industries Ltd1,245
进行中（未招募）
1 期
A clinical study in subjects with multiple sclerosis who successfullycompleted the MS-LAQ-301 (ALLEGRO) study, to assess the safety oflaquinimod (experimental drug) when taken for a long period of time andhow it affects the course of the disease.aquinimod is developed for the treatment of relapsing remitting multiple sclerosis.MedDRA version: 19.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-012989-30-CZTeva Pharmaceutical Industries Ltd542
进行中（未招募）
1 期
A clinical study in subjects with multiple sclerosis who successfullycompleted the MS-LAQ-301 (ALLEGRO) study, to assess the safety oflaquinimod (experimental drug) when taken for a long period of time andhow it affects the course of the disease.EUCTR2009-012989-30-NLTeva Pharmaceutical Industries Ltd632
已完成
3 期
A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 (ALLEGRO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosisMultiple Sclerose10012303NL-OMON43625TEVA Pharma10